Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Inclusion Criteria: * Age≥18 years, ≤70 years, male or female; * Advanced collecting duct carcinoma of the kidney is diagnosed histologically or pathologically ; * Have not received anti-angiogenesis targeted drug therapy and systemic chemotherapy; * Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors); * Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1; * The expected life span is ≥12 weeks; * No contraindications for chemotherapy, with enough liver function and renal function and normal ECG recording.Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L, Hgb≥90 g/L;Renal function: serum creatinine≤1.5 folds the upper limit of normal (ULN); For patients with non-metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN; * The patients participate voluntarily and have signed the informed consent form. Exclusion Criteria: * Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures; * Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds; * Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension; * Patients with a history of HIV infection or active phase of chronic hepatitis B/C; * negative imaging examination result 4 weeks prior to enrollment); * Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs); * A history of allogeneic organ transplantation; * Patients with evidence of hemorrhagic constitution or a past history of hemorrhage; * Patients currently receiving renal dialysis; * Past or present concomitant tumors with the primary lesions or histological characteristics different from the tumors evaluated in this study, excluding other tumor cured longer than 3 years before enrollment; * Patients participating in other clinical trials simultaneously; * Other conditions unsatisfying the inclusion criteria in the investigator's opinions.